Clinical study of radiotherapy for nasopharyngeal carcinoma

Takashi Toba, Yoshiyuki Shioyama, Satoshi Nomoto, Ohga Saiji, Tadamasa Yoshitake, K. Ohnishi, K. Atsumi, H. Terashima, Hiroshi Honda, K. Nakamura

Research output: Contribution to journalArticle

Abstract

This study was a retrospective analysis of 65 patients with histologically confirmed nasopharyngeal carcinoma, who were treated at Kyushu University Hospital from 1992 to 2005. Radiotherapy consisted of once daily 1.5-2.0 Gy fractions 5 times per week to a total of 60-81 Gy. Chemotherapy was combined with radiotherapy in 61 patients. Forty-five patients received concurrent chemoradiotherapy with daily 5-FU (250 mg/body/day) or TS-1 (100mg/body/day) . Sixteen patients alternatingly received concurrent chemoradiotherapy with daily 5-FU or carboplatin (40 mg/body/day) and systemic chemotherapy consisting of cisplatin (80 mg/m2, day 1) and peplomycin (5mg/body/day, days 2-6) after 30Gy irradiation. The five-year cause-specific survival (CSS) rate was 68%. CSS significantly favored the patients without lymph node metastasis. Local recurrence was observed in 14 patients, all of whom received radiotherapy for more than 75 days. Although prolonged duration of radiotherapy caused by chemotherapy regimen or its toxicity seemed to reduce effectiveness of radiation, chemoradiotherapy for patients with nasopharyngeal carcinoma might contribute to improving their survival.

Original languageEnglish
Pages (from-to)317-322
Number of pages6
JournalJapanese Journal of Clinical Radiology
Volume53
Issue number2
Publication statusPublished - 2008

Fingerprint

Radiotherapy
Chemoradiotherapy
Drug Therapy
Fluorouracil
Peplomycin
Survival
Carboplatin
Clinical Studies
Nasopharyngeal carcinoma
Cisplatin
Survival Rate
Lymph Nodes
Radiation
Neoplasm Metastasis
Recurrence

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Toba, T., Shioyama, Y., Nomoto, S., Saiji, O., Yoshitake, T., Ohnishi, K., ... Nakamura, K. (2008). Clinical study of radiotherapy for nasopharyngeal carcinoma. Japanese Journal of Clinical Radiology, 53(2), 317-322.

Clinical study of radiotherapy for nasopharyngeal carcinoma. / Toba, Takashi; Shioyama, Yoshiyuki; Nomoto, Satoshi; Saiji, Ohga; Yoshitake, Tadamasa; Ohnishi, K.; Atsumi, K.; Terashima, H.; Honda, Hiroshi; Nakamura, K.

In: Japanese Journal of Clinical Radiology, Vol. 53, No. 2, 2008, p. 317-322.

Research output: Contribution to journalArticle

Toba, T, Shioyama, Y, Nomoto, S, Saiji, O, Yoshitake, T, Ohnishi, K, Atsumi, K, Terashima, H, Honda, H & Nakamura, K 2008, 'Clinical study of radiotherapy for nasopharyngeal carcinoma', Japanese Journal of Clinical Radiology, vol. 53, no. 2, pp. 317-322.
Toba, Takashi ; Shioyama, Yoshiyuki ; Nomoto, Satoshi ; Saiji, Ohga ; Yoshitake, Tadamasa ; Ohnishi, K. ; Atsumi, K. ; Terashima, H. ; Honda, Hiroshi ; Nakamura, K. / Clinical study of radiotherapy for nasopharyngeal carcinoma. In: Japanese Journal of Clinical Radiology. 2008 ; Vol. 53, No. 2. pp. 317-322.
@article{f53246a501ad43d4a2d683c6af54a32b,
title = "Clinical study of radiotherapy for nasopharyngeal carcinoma",
abstract = "This study was a retrospective analysis of 65 patients with histologically confirmed nasopharyngeal carcinoma, who were treated at Kyushu University Hospital from 1992 to 2005. Radiotherapy consisted of once daily 1.5-2.0 Gy fractions 5 times per week to a total of 60-81 Gy. Chemotherapy was combined with radiotherapy in 61 patients. Forty-five patients received concurrent chemoradiotherapy with daily 5-FU (250 mg/body/day) or TS-1 (100mg/body/day) . Sixteen patients alternatingly received concurrent chemoradiotherapy with daily 5-FU or carboplatin (40 mg/body/day) and systemic chemotherapy consisting of cisplatin (80 mg/m2, day 1) and peplomycin (5mg/body/day, days 2-6) after 30Gy irradiation. The five-year cause-specific survival (CSS) rate was 68{\%}. CSS significantly favored the patients without lymph node metastasis. Local recurrence was observed in 14 patients, all of whom received radiotherapy for more than 75 days. Although prolonged duration of radiotherapy caused by chemotherapy regimen or its toxicity seemed to reduce effectiveness of radiation, chemoradiotherapy for patients with nasopharyngeal carcinoma might contribute to improving their survival.",
author = "Takashi Toba and Yoshiyuki Shioyama and Satoshi Nomoto and Ohga Saiji and Tadamasa Yoshitake and K. Ohnishi and K. Atsumi and H. Terashima and Hiroshi Honda and K. Nakamura",
year = "2008",
language = "English",
volume = "53",
pages = "317--322",
journal = "Japanese Journal of Clinical Radiology",
issn = "0009-9252",
publisher = "Kanehara Shuppan Co. Ltd",
number = "2",

}

TY - JOUR

T1 - Clinical study of radiotherapy for nasopharyngeal carcinoma

AU - Toba, Takashi

AU - Shioyama, Yoshiyuki

AU - Nomoto, Satoshi

AU - Saiji, Ohga

AU - Yoshitake, Tadamasa

AU - Ohnishi, K.

AU - Atsumi, K.

AU - Terashima, H.

AU - Honda, Hiroshi

AU - Nakamura, K.

PY - 2008

Y1 - 2008

N2 - This study was a retrospective analysis of 65 patients with histologically confirmed nasopharyngeal carcinoma, who were treated at Kyushu University Hospital from 1992 to 2005. Radiotherapy consisted of once daily 1.5-2.0 Gy fractions 5 times per week to a total of 60-81 Gy. Chemotherapy was combined with radiotherapy in 61 patients. Forty-five patients received concurrent chemoradiotherapy with daily 5-FU (250 mg/body/day) or TS-1 (100mg/body/day) . Sixteen patients alternatingly received concurrent chemoradiotherapy with daily 5-FU or carboplatin (40 mg/body/day) and systemic chemotherapy consisting of cisplatin (80 mg/m2, day 1) and peplomycin (5mg/body/day, days 2-6) after 30Gy irradiation. The five-year cause-specific survival (CSS) rate was 68%. CSS significantly favored the patients without lymph node metastasis. Local recurrence was observed in 14 patients, all of whom received radiotherapy for more than 75 days. Although prolonged duration of radiotherapy caused by chemotherapy regimen or its toxicity seemed to reduce effectiveness of radiation, chemoradiotherapy for patients with nasopharyngeal carcinoma might contribute to improving their survival.

AB - This study was a retrospective analysis of 65 patients with histologically confirmed nasopharyngeal carcinoma, who were treated at Kyushu University Hospital from 1992 to 2005. Radiotherapy consisted of once daily 1.5-2.0 Gy fractions 5 times per week to a total of 60-81 Gy. Chemotherapy was combined with radiotherapy in 61 patients. Forty-five patients received concurrent chemoradiotherapy with daily 5-FU (250 mg/body/day) or TS-1 (100mg/body/day) . Sixteen patients alternatingly received concurrent chemoradiotherapy with daily 5-FU or carboplatin (40 mg/body/day) and systemic chemotherapy consisting of cisplatin (80 mg/m2, day 1) and peplomycin (5mg/body/day, days 2-6) after 30Gy irradiation. The five-year cause-specific survival (CSS) rate was 68%. CSS significantly favored the patients without lymph node metastasis. Local recurrence was observed in 14 patients, all of whom received radiotherapy for more than 75 days. Although prolonged duration of radiotherapy caused by chemotherapy regimen or its toxicity seemed to reduce effectiveness of radiation, chemoradiotherapy for patients with nasopharyngeal carcinoma might contribute to improving their survival.

UR - http://www.scopus.com/inward/record.url?scp=40149108042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40149108042&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 317

EP - 322

JO - Japanese Journal of Clinical Radiology

JF - Japanese Journal of Clinical Radiology

SN - 0009-9252

IS - 2

ER -